Cancer is the second leading cause of death in the US. The total number of new cancer cases are expected to increase with the aging population. As more people are diagnosed and treated with cancer, more therapeutically effective and cost-effective treatments become increasingly important.
Systemic chemotherapy has been first-line therapy for decades, but nearly all patients suffer from some degree of systemic toxicity. About half of chemotherapy patients suffer debilitating complications and are forced to either reduce chemotherapy dosing or terminate chemotherapy treatment. These patients are unable to receive the full benefit of chemotherapy.
Isola Therapeutics is developing a local drug delivery system to more effectively treat cancer while reducing systemic complications.